Press Space to continue
It’s really only been possible to start doing that with AI.
Press Space to continue
Topos Bio CEO Ryan Zarcone explains why designing drugs for Parkinson's and Alzheimer's is almost impossible for humans, but a perfect problem for AI: "When a chemist designs a drug for a protein, the model is static. I have this protein, it has a shape, and I’m trying to fill that shape with a drug." "These really dynamic proteins, like those involved in Parkinson’s and Alzheimer’s, don’t have one shape. They have potentially thousands of different shapes that they’re constantly…
ToposBio@ToposBioSep 30
Today we are announcing Topos-2, our next-generation model for generating the full range of shapes a protein can take, across the order-disorder spectrum. We are also previewing Topos-Bind: to our knowledge, the first generative model to capture the range of shapes for disordered proteins bound to small molecules. Read the technical blog post here: https://t.co/BLAXHAgsH4 (1/7)
View